<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01742221</url>
  </required_header>
  <id_info>
    <org_study_id>2012-002</org_study_id>
    <nct_id>NCT01742221</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure</brief_title>
  <official_title>A Phase 1b, Single-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HemaMax™ (rHuIL-12) in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neumedicines Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department of Health and Human Services</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Neumedicines Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of
      HemaMax in healthy male and female volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of HemaMax in healthy subjects.</measure>
    <time_frame>3 months</time_frame>
    <description>Number of subjects with adverse events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To characterize the pharmacokinetics, pharmacodynamics and immunogenicity of HemaMax in healthy subjects</measure>
    <time_frame>3 months</time_frame>
    <description>To evaluate PK parameters AUC, Cmax, Tmax, t ½, Vz/F, and CL/F for HemaMax. To evaluate biological response parameters following HemaMax.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hematopoietic Syndrome Due to Acute Radiation Syndrome</condition>
  <arm_group>
    <arm_group_label>HemaMax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single subcutaneous dose of HemaMax</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single subcutaneous dose of Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HemaMax</intervention_name>
    <description>Placebo</description>
    <arm_group_label>HemaMax</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>rHuIL-12</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and Female subjects, who have signed the informed consent form must meet all of
             the following criteria

               1. 18 to 45 years of age

               2. Body mass index (BMI) &gt; 19 and &lt; 0 kg/m2

               3. Normal ECG, vital signs and laboratory test results

               4. Use of effective birth control method and abstinence from sex

               5. Negative pregnancy test and drug screen

        Exclusion Criteria:

          -  Subjects with any of the following characteristics will be considered ineligible:

               1. History of clinically significant renal, hepatic pulmonary, cardiovascular,
                  cerebrovascular, gastrointestinal, metabolic, hematological, endocrine,
                  urological, immunological, neurologic or psychiatric disorders or connective
                  tissue disease

               2. Positive for human immunodeficiency virus (HIV), Hepatitis B, or surface antigen
                  (HBsAg) or Hepatitis C antibody, tuberculosis (TB)

               3. Current drug or alcohol addiction

               4. History of clinically significant allergy of any kind

               5. Prior use of IL-12 or HemaMax

               6. Use of any approved or investigational biologic agents or vaccinations of any
                  kind in last 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Siebers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2012</study_first_submitted>
  <study_first_submitted_qc>December 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2012</study_first_posted>
  <last_update_submitted>April 25, 2013</last_update_submitted>
  <last_update_submitted_qc>April 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety and Tolerability, Cytokines, Acute Radiation Syndrome, Hematopoietic Syndrome, Radiation Countermeasure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Radiation Injuries</mesh_term>
    <mesh_term>Acute Radiation Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

